Physician profile
Stephen K Lee
NPI 1053327288
$7,809.29
in general payments reported to CMS, 2019-2025
22 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,817 · 2020: $1,227 · 2021: $1,660 · 2022: $745 · 2023: $162 · 2024: $76.28 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $360.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,172.77 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $560.11 | 2019-2021 | |
| Pfizer INC. | $527.28 | 2019-2024 | |
| Novo Nordisk INC | $524.41 | 2019-2022 | |
| Abbvie INC. | $423.33 | 2019-2022 | |
| Amarin Pharma, INC. | $339.61 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $308.93 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $270.69 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $265.06 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $233.08 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Biohaven Pharmaceutical Holding Company LTD. | $187.89 | 2022 | |
| Bardy Diagnostics, INC. | $187.22 | 2020-2021 | |
| Amgen INC. | $184.14 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $158.15 | 2019-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $130.71 | 2021-2025 | Zoryve |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $117.80 | 2019 | |
| Stryker Corporation | $78.52 | 2025 | Na |
| Radius Health, INC. | $52.20 | 2019 | |
| Glaxosmithkline, LLC. | $32.38 | 2023 | Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.36 | 2019-2020 | |
| Sanofi Pasteur INC. | $14.53 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.